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A 70-year-old woman with autoimmune haemolytic anaemia (IgG1-mediated) had been under several immunosuppressant agents for 8 years with a satisfactory response until she was admitted for acute severe haemolytic anaemia. The patient was successfully treated with intravenous rituximab (RTX), four infusions (500 mg EV). Recurrence occurred 9 months later and RTX was reintroduced (four infusions). One week after the third RTX infusion, the patient noticed a well-defined erythematous plaque on the right arm with burning sensation. After spontaneous resolution in 2 weeks, the patient received the fourth RTX infusion. One week later, an erythematous plaque on the right arm and forearm appeared, persisting for 6 weeks before dissemination with accompanying burning sensation. The patient was then referred to a Dermatology appointment, presenting with bilateral and symmetrically distributed welldefined erythematous plaques, with a smooth surface, arranged in a concentric and polycyclic shapes and located on the extensor surface of both arms/forearms and posterior surface of the thighs, hips and glutei (Fig. 1) . No other relevant signs or symptoms were present.
The patient had a typical cushingoid phenotype, osteoporosis, hypertension and heart failure and was currently taking prednisolone 25 mg daily (0.3 mg/kg daily), esomeprazole, bisoprolol, furosemide, alendronic acid and colecalciferol. No new drug was started on the preceding months. Malignancies and infections (including borreliosis) were excluded. Diagnostic criteria for systemic lupus erythematous were not met. The patient did not recall similar annular rashes before the use of RTX. A punch biopsy was performed and histopathological examination revealed an elastotic and edematous dermis, with a lympho-histiocytic perivascular inflammatory infiltrate as well as focal erythrocyte extravasation. Minor aspects: mild hyperkeratosis and focal spongiosis.
No further RTX infusions were given and gradual regression of the dermatosis occurred in 2 weeks. Clinical history and skin histology were compatible with the deep form of erythema annulare centrifigum.
Discussion
Erythema annulare centrifugum (EAC) is a variant of figurate erythema, presenting with erythematous macules and papules that enlarge slowly by peripheral extension to form ringed, arcuate or polycyclic figures with central clearing. It has been traditionally divided into superficial and deep forms, the former presenting with trailing scales on the inside border and the latter infiltrated plaques with no superficial scale.
1,2 After confirming the diagnosis and excluding common assumed triggers (infections, malignancy and pregnancy), 2 a definite aetiology is still difficult to prove. EAC can be chronic or self-limiting and immunosuppressive medications are commonly given. 2 Rituximab is a chimeric murine/human monoclonal antibody directed against the B-cell antigen: CD20. The cutaneous sideeffects of RTX are frequent, but usually not serious. 3 They can be divided into infusion reactions, infections, skin malignancies and other, including Erythema Multiforme, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Bullous dermatitis and Paraneoplastic Pemphigus. 4 The onset of the reported reactions has varied from 1 to 13 weeks following RTX exposure. 3 The temporal relationship with RTX administration and a concomitant autoimmune disease makes the authors speculate about the importance of immunological disturbance on the pathogenesis of EAC.
In conclusion
• Erythema annulare centrifugum represents a clinical reaction pattern rather than a specific clinicopathological entity. 1 • To the authors' knowledge, this is the first reported case of EAC after RTX therapy. Secukinumab improves the signs and symptoms of moderateto-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study Editor Psoriasis affecting the hands and/or feet has greater impact on quality of life than other forms of the disease and is more difficult-to-treat, as topical and systemic therapies and phototherapy are often ineffective, difficult to administer, and/or limited by toxicity effects.
1,2 Biologics targeting pro-inflammatory cytokines such as tumour necrosis factor (TNF) and interleukin (IL)-12/23 have shown efficacy in managing moderate-to-severe plaque psoriasis 3, 4 and have also demonstrated efficacy in the treatment of difficult-to-treat disease, including hand/foot psoriasis. [5] [6] [7] Secukinumab (Novartis Pharma AG, Basel, Switzerland)
is a fully human IgG1j anti-IL-17A monoclonal antibody that selectively suppresses the inflammatory cascade induced by IL-17A. The efficacy and safety of secukinumab for the treatment of moderate-to-severe psoriasis has been demonstrated in proofof-concept and other phase 2 studies. [8] [9] [10] In a post hoc analysis of a multicentre, randomized, double-blind, placebo-controlled, dose-ranging phase 2 study, 9 we evaluated the effects of secukinumab in a subgroup of subjects with moderate-to-severe psoriasis involving the hands and/or feet. A complete description of the design/methods for the primary study was published previously.
9 Subjects (N = 125) were ran- 
